Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK0801 in Bone Marrow Failure Syndrome
NCT03773393Phase 1Active, not recruiting
- Start
- May 2019
- Primary completion
- May 2027
- Modality
- Regulatory T Cells (Tregs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CK0801 in bone marrow failure syndrome (BMFS). Primary endpoints: Number of Participants with Severe Infusion Toxicity as Assessed by CTCAE v4.0 at 24 hours, Number of Participants with Regimen Related Death at 30 days and 1 more. Started May 2019; status: active, not recruiting.
02
Drugs
CK0801
03
Conditions
bone marrow failure syndrome (BMFS)
Beyond the preview
Go deeper on NCT03773393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773393.